132 related articles for article (PubMed ID: 32807821)
1. A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD
Silveira SC; Buhagiar-Labarchède G; Onclercq-Delic R; Gemble S; Bou Samra E; Mameri H; Duchambon P; Machon C; Guitton J; Amor-Guéret M
Sci Rep; 2020 Aug; 10(1):13907. PubMed ID: 32807821
[TBL] [Abstract][Full Text] [Related]
2. Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA.
Gemble S; Ahuja A; Buhagiar-Labarchède G; Onclercq-Delic R; Dairou J; Biard DS; Lambert S; Lopes M; Amor-Guéret M
PLoS Genet; 2015 Jul; 11(7):e1005384. PubMed ID: 26181065
[TBL] [Abstract][Full Text] [Related]
3. A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation.
Gemble S; Buhagiar-Labarchède G; Onclercq-Delic R; Biard D; Lambert S; Amor-Guéret M
J Cell Sci; 2016 Aug; 129(16):3167-77. PubMed ID: 27383768
[TBL] [Abstract][Full Text] [Related]
4. Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity.
Gemble S; Buhagiar-Labarchède G; Onclercq-Delic R; Jaulin C; Amor-Guéret M
Cell Cycle; 2017 Jun; 16(11):1128-1135. PubMed ID: 28463527
[TBL] [Abstract][Full Text] [Related]
5.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
6. Alkyladenine DNA glycosylase deficiency uncouples alkylation-induced strand break generation from PARP-1 activation and glycolysis inhibition.
Alhumaydhi FA; de O Lopes D; Bordin DL; Aljohani ASM; Lloyd CB; McNicholas MD; Milano L; Charlier CF; Villela I; Henriques JAP; Plant KE; Elliott RM; Meira LB
Sci Rep; 2020 Feb; 10(1):2209. PubMed ID: 32042007
[TBL] [Abstract][Full Text] [Related]
7. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
[TBL] [Abstract][Full Text] [Related]
8. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
9. NAD
Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
[TBL] [Abstract][Full Text] [Related]
10. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Bajrami I; Kigozi A; Van Weverwijk A; Brough R; Frankum J; Lord CJ; Ashworth A
EMBO Mol Med; 2012 Oct; 4(10):1087-96. PubMed ID: 22933245
[TBL] [Abstract][Full Text] [Related]
12. Cytidine deaminase deficiency in mice enhances genetic instability but limits the number of chemically induced colon tumors.
Onclercq-Delic R; Buhagiar-Labarchède G; Leboucher S; Larcher T; Ledevin M; Machon C; Guitton J; Amor-Guéret M
Cancer Lett; 2023 Feb; 555():216030. PubMed ID: 36496104
[TBL] [Abstract][Full Text] [Related]
13. Weight Loss Is Associated With Increased NAD(+)/SIRT1 Expression But Reduced PARP Activity in White Adipose Tissue.
Rappou E; Jukarainen S; Rinnankoski-Tuikka R; Kaye S; Heinonen S; Hakkarainen A; Lundbom J; Lundbom N; Saunavaara V; Rissanen A; Virtanen KA; Pirinen E; Pietiläinen KH
J Clin Endocrinol Metab; 2016 Mar; 101(3):1263-73. PubMed ID: 26760174
[TBL] [Abstract][Full Text] [Related]
14. NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos cell death.
Martínez-Morcillo FJ; Cantón-Sandoval J; Martínez-Navarro FJ; Cabas I; Martínez-Vicente I; Armistead J; Hatzold J; López-Muñoz A; Martínez-Menchón T; Corbalán-Vélez R; Lacal J; Hammerschmidt M; García-Borrón JC; García-Ayala A; Cayuela ML; Pérez-Oliva AB; García-Moreno D; Mulero V
PLoS Biol; 2021 Nov; 19(11):e3001455. PubMed ID: 34748530
[TBL] [Abstract][Full Text] [Related]
15. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Kudo K; Nomura M; Sakamoto Y; Ito S; Morita M; Kawai M; Yamashita Y; Ito K; Yamada H; Shima H; Yaegashi N; Tanuma N
FEBS Lett; 2020 May; 594(9):1379-1388. PubMed ID: 31950503
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
17. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
[TBL] [Abstract][Full Text] [Related]
19. The NAD(+) salvage pathway modulates cancer cell viability via p73.
Sharif T; Ahn DG; Liu RZ; Pringle E; Martell E; Dai C; Nunokawa A; Kwak M; Clements D; Murphy JP; Dean C; Marcato P; McCormick C; Godbout R; Gujar SA; Lee PW
Cell Death Differ; 2016 Apr; 23(4):669-80. PubMed ID: 26586573
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
